Epilepsy and Alzheimer's Disease: Current Concepts and Treatment Perspective on Two Closely Related Pathologies
- PMID: 35524669
- PMCID: PMC9886839
- DOI: 10.2174/1570159X20666220507020635
Epilepsy and Alzheimer's Disease: Current Concepts and Treatment Perspective on Two Closely Related Pathologies
Abstract
The literature on epileptic seizures in Alzheimer's disease has significantly increased over the past decades. Remarkably, several studies suggest a bi-directional link between these two common neurological diseases, with either condition carrying a nearly 2-fold risk of contracting the other in comparison to healthy subjects. In this respect, evidence from both clinical and preclinical studies indicates that epileptogenesis and neurodegeneration possibly share common underlying mechanisms. However, the precise association between epileptogenesis and neurodegeneration still needs to be fully elucidated. Targeted intervention to reduce abnormal network hyperexcitability might constitute a therapeutic strategy to postpone the onset of later neurodegenerative changes and consequent cognitive decline by many years in patients. By virtue of this, an early diagnosis and treatment of seizures in patients with Alzheimer's disease should be pursued. To date, no guidelines are available for treating epileptic activity in this context, largely due to the paucity of studies sufficient to answer the related questions. Accordingly, clinical trials are mandatory, not only to inform clinicians about symptomatic management of seizures in Alzheimer's disease patients but also to detect if treatment with antiseizure medications could have disease-modifying effects. Moreover, it will be fundamental to expand the application of animal models of Alzheimer's disease to comorbid conditions, such as epilepsy both to reveal the mechanisms underlying seizure onset and to better define their role in cognitive decline. Such models could also be useful to identify pharmacological compounds having therapeutically effectiveness as well as reliable early biomarkers for seizures in Alzheimer's disease.
Keywords: Alzheimer’s disease; Epilepsy; network hyperexcitability; neurological comorbidities; perspective of treatment; pharmacology.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Antiseizure Medications in Alzheimer's Disease from Preclinical to Clinical Evidence.Int J Mol Sci. 2023 Aug 10;24(16):12639. doi: 10.3390/ijms241612639. Int J Mol Sci. 2023. PMID: 37628821 Free PMC article. Review.
-
From here to epilepsy: the risk of seizure in patients with Alzheimer's disease.Epileptic Disord. 2016 Mar;18(1):1-12. doi: 10.1684/epd.2016.0808. Epileptic Disord. 2016. PMID: 26907471 Review.
-
Epileptic activity in Alzheimer's disease: causes and clinical relevance.Lancet Neurol. 2017 Apr;16(4):311-322. doi: 10.1016/S1474-4422(17)30044-3. Lancet Neurol. 2017. PMID: 28327340 Free PMC article. Review.
-
Tackling seizures in patients with Alzheimer's disease.Expert Rev Neurother. 2023 Jul-Dec;23(12):1131-1145. doi: 10.1080/14737175.2023.2278487. Epub 2023 Dec 15. Expert Rev Neurother. 2023. PMID: 37946507 Review.
-
Mechanisms Involved in Epileptogenesis in Alzheimer's Disease and Their Therapeutic Implications.Int J Mol Sci. 2022 Apr 13;23(8):4307. doi: 10.3390/ijms23084307. Int J Mol Sci. 2022. PMID: 35457126 Free PMC article. Review.
Cited by
-
Investigating the causal relationship between immune cell and Alzheimer's disease: a mendelian randomization analysis.BMC Neurol. 2024 Mar 18;24(1):98. doi: 10.1186/s12883-024-03599-y. BMC Neurol. 2024. PMID: 38500057 Free PMC article.
-
Alzheimer's Disease and Epilepsy: Exploring Shared Pathways and Promising Biomarkers for Future Treatments.J Clin Med. 2024 Jul 1;13(13):3879. doi: 10.3390/jcm13133879. J Clin Med. 2024. PMID: 38999445 Free PMC article. Review.
-
Antiseizure Medications in Alzheimer's Disease from Preclinical to Clinical Evidence.Int J Mol Sci. 2023 Aug 10;24(16):12639. doi: 10.3390/ijms241612639. Int J Mol Sci. 2023. PMID: 37628821 Free PMC article. Review.
References
-
- James S.L., Abate D., Abate K.H., Abay S.M., Abbafati C., Abbasi N., Abbastabar H., Abd-Allah F., Abdela J. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858. doi: 10.1016/S0140-6736(18)32279-7. - DOI - PMC - PubMed
-
- Sen A., Akinola M., Tai X.Y., Symmonds M., Davis Jones G., Mura S., Galloway J., Hallam A., Chan J.Y.C., Koychev I., Butler C., Geddes J., Van Der Putt R., Thompson S., Manohar S.G., Frangou E., Love S., McShane R., Husain M. An investigation of le-vetiracetam in Alzheimer’s disease (ILiAD): A double-blind, placebo-controlled, randomised crossover proof of concept study. Trials. 2021;22(1):508. doi: 10.1186/s13063-021-05404-4. - DOI - PMC - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous